Recent studies have indicated that nitric oxide may play a role in inhalation anaesthesia. Inhibition of nitric oxide synthase reduces the minimum alveolar concentration (MAC) for inhalation anaesthetics and decreases cerebellar nitric oxide synthase (NOS) activity in rats. In this study, we have explored further the role of nitric oxide in isoflurane anaesthesia by examining the effects of a nitric oxide scavenger, 2-(4-carboxyphenyl)-4,4,5,5-tetramethylimidazoline-1 -oxyl-3-oxide (carboxy-PTIO 0.075-0.6 mg kg" 1 ) on MAC values and cerebellar NOS activity in rats. Bolus injection of carboxy-PTIO at doses greater than 0.15 mg kg" 1 reduced the MAC value of isoflurane (mean 1.36 (SEM 0.07)% at 0.15 mg kg" 1 , 1.39 (0.14)% at 0.3 mg kg" 1 and 1.31 (0.06)% at 0.6 mg kg" 1 vs control value of 1.61 (0.19)%). Administration of carboxy-PTIO 0.125 and 0.15 mg kg"' resulted in increased cerebellar NOS activity during isoflurane anaesthesia (P<0.05). These findings suggest that the level of nitric oxide may set a baseline from which isoflurane then acts. BrJAnaesth 1999; 83:948-50 
Nitric oxide is a neurotransmitter known to be important in mediating central nociceptive pathways, and may also be involved in the mechanisms underlying wakefulness and anaesthesia. 1 2 The physiological and pathological effects of nitric oxide generation are usually examined indirectly via suppressing nitric oxide synthase (NOS) with inhibitors such as nitro G -L-arginine methyl ester (L-NAME) and N G -monomethyl-L-arginine (L-NMMA). Administration of these NOS inhibitors reduces the minimum alveolar concentration (MAC) of halothane and isoflurane in rats, rabbits and mice. 2 3 Carboxy-PTIO (2-(4-carboxyphenyl)-4,4,5,5-tetramethylimidazoline-1 -oxyl-3-oxide) reacts rapidly with nitric oxide to yield nitrogen dioxide and has been used as a nitric oxide scavenger to test the importance of nitric oxide in various physiological conditions. 4 In this study, we have investigated the effects of carboxy-PTIO on the anaesthetic thresholds of isoflurane and measured NOS activity in the cerebellum when nitric oxide was scavenged by carboxy-PTIO.
Methods and results
After obtaining approval from the Institutional Animal Care Committee, we examined changes in isoflurane MAC and cerebellar NOS activity in response to a nitric oxide scavenger. We studied 54 adult male Wistar rats (345 ±8 g), allocated to one of six isoflurane groups. Preliminary data suggested using i.v. doses of carboxy-PTIO of 0.6, 0.3, 0.15, 0.125, 0.1 and 0.075 mg kg" 1 in rats during isoflurane. anaesthesia. Control rats received the same volume of normal saline. One hour later, all rats were placed in a clear plastic cone individually and anaesthetized with 5% isoflurane in oxygen 1 litre min" 1 for 3-5 min. Tracheostomy was performed with a short-cut 16-gauge polyethylene catheter. Mechanical ventilation was controlled with an IPPB Respirator UR-100 (Shin-Ei Industry Co., Ltd, Japan) and adjusted according to arterial blood-gas data. A femoral artery was cannulated with PE50 tubing for measurement of systemic arterial pressure (Datex, Cardiocap, CM-104-28-01) and sampling of blood for gas analysis. Gas samples were obtained continuously from the tracheostomy catheter by a three-way connector to an infrared gas analyser (Ultima Capnomac, sampling rate 200 ml min" 1 ), which was designed to allow continuous monitoring of inspired and end-tidal concentrations of isoflurane and carbon dioxide. Body temperature was maintained with a heating blanket and a heating lamp.
The MAC of isoflurane was determined as described in our previous studies; 3 these methods were adapted originally from those of Eger and colleagues. After MAC values were determined, rats were killed by disarticulation and the 1 for heart rate). The carboxy-PTIO-induced changes in arterial pressure were not accompanied by a change in heart rate. No adverse effects such as hypoxia, hypercapnia or acidosis were observed at any dose of carboxy-PTIO.
Comment
We have demonstrated that the MAC of isoflurane was reduced gradually by i.v. administration of carboxy-PTIO and a ceiling effect was observed at doses greater than 0.15 mg kg" 1 . These results are consistent with our previous findings that the NOS inhibitor, L-NAME, decreased the MAC of isoflurane in rats and rabbits, 3 and also confirm the findings of others. 1 2 Both scavenging and inhibiting the production of nitric oxide in the central nervous system may result in lower endogenous nitric oxide concentrations.
Decreased nitric oxide concentrations in the central nervous system may have a sedative, analgesic or anaesthetic effect.
2 Carboxy-PTIO is a stable organic radical that was developed by Yoshida and colleagues at Kumamoto University. 4 This reagent reacts rapidly with nitric oxide to yield -NO 2 and has been used as a scavenger to test the importance of nitric oxide in various physiological conditions, especially the relationship between nitric oxide and vascular tone at various sites. 4 NOS inhibitors, such as L-NAME or its analogues, are used generally to investigate changes in the thresholds of inhalation anaesthetics. 1 2 Yoshida and colleagues demonstrated the inhibitory effect of carboxy-PTIO on acetylcholine-induced vasodilatation of rabbit aorta rings. 4 However, the effect of the nitric oxide scavenger, carboxy-PTIO, on inhalation anaesthetics has not yet been reported. In this study, we examined the effects of carboxy-PTIO on the threshold of isoflurane and demonstrated that i.v. administration of carboxy-PTIO caused a dose-dependent decrease in the MAC of isoflurane in vivo.
Inhalation anaesthetics are generally thought to inhibit NOS activity and decrease cGMP concentrations in vivo in the cerebellum and in other regions of the brain. 5 However, some studies failed to demonstrate inhibition of in vitro NOS activity. 6 The mechanism of inhibition of the nitric oxide-guanylyl cyclase signalling pathway by inhalation anaesthetics is unknown. Terasako and colleagues reported that halothane inactivates NOS or related cofactors, and isoflurane may interact with the NMDA receptor, receptorcoupled G-protein or calcium channels. 5 Zuo and Johns suggested that NMDA stimulation of the brain nitric oxideguanylyl cyclase signalling pathway may be inhibited by inhalation anaesthetics. 6 Pajewski and colleagues stated that inhalation anaesthetics appear to inhibit the nitric oxideguanylyl cyclase signalling pathway proximal to activation of guanylyl cyclase. 2 We found that carboxy-PTIO increased NOS activity in the cerebellum in the isoflurane group. The increased cerebellar NOS activity during isoflurane anaesthesia may be a result of conversion of nitric oxide to NO 2 by carboxy-PTIO, that is decreased nitric oxide concentration may activate cerebellar NOS to produce nitric oxide.
Carboxy-PTIO is a promising reagent for nitric oxide research and clinical applications. Yoshida and colleagues reported that carboxy-PTIO exhibits a potent therapeutic value in endotoxin shock through its direct nitric oxide scavenging action. 4 In our study, carboxy-PTIO increased systolic arterial pressure during isoflurane anaesthesia at most doses (0.075, 0.1, 0.15 and 0.6 mg kg" 1 ). There were no adverse effects such as severe hypertension or stroke.
In summary, we have demonstrated that carboxy-PTIO, a new class of nitric oxide scavenger, decreased the threshold of isoflurane and increased cerebellar NOS activity during isoflurane anaesthesia. These findings suggest that nitric oxide may be acting on an independent pathway related to 'arousal' which, when inhibited, influences the efficacy of isoflurane to induce anaesthesia.
